Effects of oxcarbazepine and phenytoin on the EEG and cognition in healthy volunteers

M. C. Salinsky; D. C. Spencer; B. S. Oken; D. Storzbach

doi:10.1016/j.yebeh.2004.07.011

Effects of oxcarbazepine and phenytoin on the EEG and cognition in healthy volunteers

M. C. Salinsky
, D. C. Spencer
, B. S. Oken
, D. Storzbach

Neurology

Research output: Contribution to journal › Article › peer-review

56 Scopus citations

Abstract

We studied the EEG and cognitive effects of oxcarbazepine (OXC) and phenytoin (PHT) using a double-blind, randomized, parallel-group design. Thirty-two healthy volunteers received a maximum of 1200 mg of OXC or 360 mg of PHT. EEG and cognitive testing were performed at baseline and after 12 weeks of treatment. For each subject and measure, test-retest Z scores were calculated from regression equations derived from 73 healthy controls. Twenty-six subjects completed the study. Both the OXC and PHT groups had significant slowing of the EEG peak frequency and increased relative theta and delta power. Differences between AEDs (antiepileptic drugs) were not significant. Significant cognitive effects were seen on 5 of 20 measures, primarily measures of motor speed and reaction time. Again, there were no significant differences between AEDs. The only significant difference between AEDs was for the POMS-Vigor scale, favoring OXC. The small sample size may have contributed to the lack of significant differences between AEDs.

Original language	English (US)
Pages (from-to)	894-902
Number of pages	9
Journal	Epilepsy and Behavior
Volume	5
Issue number	6
DOIs	https://doi.org/10.1016/j.yebeh.2004.07.011
State	Published - Dec 2004

Funding

The authors thank Renee Hohimer for psychometric testing, Debbie Johnstone, R.N., for study coordination, and James Cereghino, M.D., for valuable comments on the manuscript. This article was presented in part at the 2003 meeting of the American Epilepsy Society in Boston, MA, USA. This work was supported by an independent investigator-initiated research grant from Novartis Pharmaceuticals.

Funders
Novartis Pharmaceuticals Corporation

Keywords

Cognition
EEG
Neurotoxicity
Oxcarbazepine
Phenytoin

ASJC Scopus subject areas

Neurology
Clinical Neurology
Behavioral Neuroscience

Access to Document

10.1016/j.yebeh.2004.07.011

Cite this

@article{eb1cfaa64341465f875a5afb93cc6f2f,

title = "Effects of oxcarbazepine and phenytoin on the EEG and cognition in healthy volunteers",

abstract = "We studied the EEG and cognitive effects of oxcarbazepine (OXC) and phenytoin (PHT) using a double-blind, randomized, parallel-group design. Thirty-two healthy volunteers received a maximum of 1200 mg of OXC or 360 mg of PHT. EEG and cognitive testing were performed at baseline and after 12 weeks of treatment. For each subject and measure, test-retest Z scores were calculated from regression equations derived from 73 healthy controls. Twenty-six subjects completed the study. Both the OXC and PHT groups had significant slowing of the EEG peak frequency and increased relative theta and delta power. Differences between AEDs (antiepileptic drugs) were not significant. Significant cognitive effects were seen on 5 of 20 measures, primarily measures of motor speed and reaction time. Again, there were no significant differences between AEDs. The only significant difference between AEDs was for the POMS-Vigor scale, favoring OXC. The small sample size may have contributed to the lack of significant differences between AEDs.",

keywords = "Cognition, EEG, Neurotoxicity, Oxcarbazepine, Phenytoin",

author = "Salinsky, \{M. C.\} and Spencer, \{D. C.\} and Oken, \{B. S.\} and D. Storzbach",

note = "Funding Information: The authors thank Renee Hohimer for psychometric testing, Debbie Johnstone, R.N., for study coordination, and James Cereghino, M.D., for valuable comments on the manuscript. This article was presented in part at the 2003 meeting of the American Epilepsy Society in Boston, MA, USA. This work was supported by an independent investigator-initiated research grant from Novartis Pharmaceuticals. ",

year = "2004",

month = dec,

doi = "10.1016/j.yebeh.2004.07.011",

language = "English (US)",

volume = "5",

pages = "894--902",

journal = "Epilepsy and Behavior",

issn = "1525-5050",

publisher = "Academic Press Inc.",

number = "6",

}

TY - JOUR

T1 - Effects of oxcarbazepine and phenytoin on the EEG and cognition in healthy volunteers

AU - Salinsky, M. C.

AU - Spencer, D. C.

AU - Oken, B. S.

AU - Storzbach, D.

N1 - Funding Information: The authors thank Renee Hohimer for psychometric testing, Debbie Johnstone, R.N., for study coordination, and James Cereghino, M.D., for valuable comments on the manuscript. This article was presented in part at the 2003 meeting of the American Epilepsy Society in Boston, MA, USA. This work was supported by an independent investigator-initiated research grant from Novartis Pharmaceuticals.

PY - 2004/12

Y1 - 2004/12

N2 - We studied the EEG and cognitive effects of oxcarbazepine (OXC) and phenytoin (PHT) using a double-blind, randomized, parallel-group design. Thirty-two healthy volunteers received a maximum of 1200 mg of OXC or 360 mg of PHT. EEG and cognitive testing were performed at baseline and after 12 weeks of treatment. For each subject and measure, test-retest Z scores were calculated from regression equations derived from 73 healthy controls. Twenty-six subjects completed the study. Both the OXC and PHT groups had significant slowing of the EEG peak frequency and increased relative theta and delta power. Differences between AEDs (antiepileptic drugs) were not significant. Significant cognitive effects were seen on 5 of 20 measures, primarily measures of motor speed and reaction time. Again, there were no significant differences between AEDs. The only significant difference between AEDs was for the POMS-Vigor scale, favoring OXC. The small sample size may have contributed to the lack of significant differences between AEDs.

AB - We studied the EEG and cognitive effects of oxcarbazepine (OXC) and phenytoin (PHT) using a double-blind, randomized, parallel-group design. Thirty-two healthy volunteers received a maximum of 1200 mg of OXC or 360 mg of PHT. EEG and cognitive testing were performed at baseline and after 12 weeks of treatment. For each subject and measure, test-retest Z scores were calculated from regression equations derived from 73 healthy controls. Twenty-six subjects completed the study. Both the OXC and PHT groups had significant slowing of the EEG peak frequency and increased relative theta and delta power. Differences between AEDs (antiepileptic drugs) were not significant. Significant cognitive effects were seen on 5 of 20 measures, primarily measures of motor speed and reaction time. Again, there were no significant differences between AEDs. The only significant difference between AEDs was for the POMS-Vigor scale, favoring OXC. The small sample size may have contributed to the lack of significant differences between AEDs.

KW - Cognition

KW - EEG

KW - Neurotoxicity

KW - Oxcarbazepine

KW - Phenytoin

UR - https://www.scopus.com/pages/publications/10844278240

UR - https://www.scopus.com/pages/publications/10844278240#tab=citedBy

U2 - 10.1016/j.yebeh.2004.07.011

DO - 10.1016/j.yebeh.2004.07.011

M3 - Article

C2 - 15582838

AN - SCOPUS:10844278240

SN - 1525-5050

VL - 5

SP - 894

EP - 902

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

IS - 6

ER -

Effects of oxcarbazepine and phenytoin on the EEG and cognition in healthy volunteers

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this